openPR Logo
Press release

In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%, claims Roots Analysis

11-21-2020 05:36 PM CET | Health & Medicine

Press release from: Roots Analysis

In silico drug discovery services market is likely to be worth USD

Owing to their cost and time saving potential, in silico tools are widely used in modern pharmacological research; several companies have developed novel tools, which are specifically designed to accelerate and augment the drug discovery process.

Roots Analysis has announced the addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” report to its list of offerings.

Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.

To order this 290+ page report, which features 120+ figures and 130+ tables, please visit this link https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Key Market Insights

Over 90 players currently claim to provide in silico drug discovery services for biologics
More than 70% of these companies are small and mid-sized firms. Further, close to 60% of the CROs engaged in this domain, claim to provide services to both pharmaceutical companies and academic institutes. It is worth mentioning that about 30% of players presently offer end-to-end drug discovery services

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Over 150 software solutions are currently available for use in drug discovery
Around 90 companies are currently providing software tools, web applications and other technology platforms for drug discovery. Examples of popular softwares include (in alphabetical order) FORECASTER SUITE, MOPAC2016™, PKPlus™, REAL Space Navigator, SaaS Platform and VolSurf+.

Nearly 80% of in silico drug discovery service providers are based in the developed geographies
This can be attributed to the relatively high adoption of the in silico approach by players based in Europe and North America. On the other hand, there are companies that are using this approach for drug discovery operations, in emerging regions, such as India and China, as well.

Around 40% of the companies claim to specialize in antibodies, proteins and peptides
Within the antibodies segment, nearly 60% of in silico service offerings are focused on the discovery of monoclonal antibodies. This is followed by companies providing services for antibody fragments (43%), bispecific antibodies (34%) and polyclonal antibodies (26%).

Using in silico solutions / tools is estimated to save ~35% of the overall drug discovery cost
By 2030, we anticipate net, annual cost savings of over USD 23 billion to be brought about by the adoption of in silico tools in large molecule drug discovery processes. The computation approach also enables researchers to expedite the overall process, thereby, saving a significant amount of time, as well.

North America and Europe are anticipated to capture over 75% of the market share by 2030
Within North America, US is anticipated to hold the 90% of the market share. It is worth mentioning that the market in Asia-Pacific region is anticipated to grow at a relatively faster rate (16.1%).

To request a sample copy / brochure of this report, please visit this link https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Key Questions Answered
Who are the leading in silico service providers for discovery of different types of large molecule drugs?
What are the key challenges associated with the discovery of large molecule drugs?
What is the likely cost saving opportunity associated with the use of in silico tools?
What are the key computational approaches being used by in silico service providers for drug discovery operations?
What are the popular business strategies being used by in silico drug discovery service providers?
How is the current and future market opportunity likely to be distributed across key market segments?

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

The USD 124 million (by 2030) financial opportunity within the in silico drug discovery market for large molecules has been analyzed across the following segments:
Key Drug Discovery Steps
Target Identification
Target Validation
Hit Generation
Hit-to-Lead
Lead Optimization

Type of Large Molecule
Antibodies
Proteins
Peptides
Nucleic Acids
Vectors

Company Size
Small
Mid-sized
Large

Target therapeutic Area
Autoimmune Disorders
Blood Disorders
Cardiovascular Disorders
Gastrointestinal and Digestive Disorders
Hormonal Disorders
Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
Infectious Diseases
Metabolic Disorders
Mental Disorders
Musculoskeletal Disorders
Neurological Disorders
Oncological Disorders
Respiratory Disorders
Skin Disorders
Urogenital Disorders
Others

Type of Sponsor
Industry Players
Non-Industry Players

Key Geographical Regions
North America
Europe
Asia-Pacific

The report features inputs from eminent industry stakeholders, according to whom the in silico approaches significantly simplifies the drug discovery process, offering better screening accuracy, as well as enabling innovators to reduce wet-lab efforts. The report includes detailed transcripts of discussions held with the following experts:
John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)
Sven Benson (Founder, candidum)
Mark Whittaker (Senior Vice President, Evotec)
Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), in silico-based service(s) portfolio and an informed future outlook.
Abzena
BioDuro
BioNTech
ChemPartner
Creative Biostructure
GenScript
LakePharma
Sundia MediTech
Sygnature Discovery
Viva Biotech

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. DNA-Encoded Libraries: Platforms and Services Market
2. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
3. Companion Diagnostics Services Market, 2020-2030

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%, claims Roots Analysis here

News-ID: 2192482 • Views: 137

More Releases from Roots Analysis

The ophthalmic drugs contract manufacturing market is estimated to be worth USD …
Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules),
Growing at an annualized rate of over 16.5%, the cell therapy manufacturing mark …
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030” report to its list of offerings. Owing to various reasons, the demand for cell therapies is anticipated to increase over the
The global autoinjectors market is projected to grow at an annualized rate of ov …
Autoinjectors have become an important part of modern healthcare, having demonstrated the potential to address a number of parenteral drug delivery related adverse events, and improve medication adherence among patients Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Autoinjectors Market (3rd Edition), 2020-2030.” For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html The report features an extensive study of the current market landscape, offering an informed
Growing at an annualized rate of over 16.5%, the cell therapy manufacturing mark …
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030” report to its list of offerings. Owing to various reasons, the demand for cell therapies is anticipated to increase over the

All 5 Releases


More Releases for Disorders

Neuroprosthetics Market 2019 Industry Segmentation by physiological disorders ar …
Neuroprosthetics Market 2019 Scenario Neuroprosthetics Market was estimated to be USD 5.28 billion in 2016 and expected to reach USD 10.48 billion by 2023. The key factors responsible for driving this are increasing in geriatric population, auditory processing disorders in kids, and increase in spinal cord treatment due to advancement in neuroprosthetics devices. The factors responsible for the positive growth of this market are increasing prevalence of neural diseases, over active bladder
11-29-2018 | Health & Medicine
Fact.MR
Global Vocal Biomarker Market to Experience Significant Growth during the Foreca …
Vocal patterns have been used by clinical psychologists and psychoanalysts for analyzing personality traits of patients, and helping creation of headway in clinical and medical investigations. Recent breakthroughs in the healthcare sector have led to the development of a unique diagnostic tool known as Vocal Biomarker Market by combining the concept of biological markers with the aforementioned methodology to analyze personality traits. Claim Sample Report For FREE: https://www.factmr.com/connectus/sample?flag=S&rep_id=719 These vocal biomarkers are
Behavioral Therapy Market Report 2018: Segmentation by Type (Anxiety Disorders, …
Global Behavioral Therapy market research report provides company profile for American Addiction Centers, ChanceLight, Haven Behavioral Healthcare, Behavioral Health Group, Center for Autism & Related Disorders, People’s Care, Magellan Health, Universal Health Services, Acadia Healthcare, Springstone and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY
Inherited Metabolic Disorders Market Felicitous over 2025
Global Inherited Metabolic Disorders (IMD) Market: Snapshot Inherited metabolic disorders (IMD), as the name suggests, are genetic conditions resulting in metabolism issues. The root cause behind maximum cases of inherited metabolic disorders (IMD) is a gene mutation that probably happened a lot many generations back. The mutation in the gene is carried through the generations. Treatment of inherited metabolic disorders (IMD) consists of dietary supplementation, dietary restrictions, drugs that thwart or regulate
Global Behavioral Rehabilitation Market By Application - Anxiety Disorders, Mood …
Researchmoz added Most up-to-date research on "Global Behavioral Rehabilitation Market By Application - Anxiety Disorders, Mood Disorders, Substance Abuse Disorders & Personality Disorders" to its huge collection of research reports. This report studies Behavioral Rehabilitation in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Retinal Disorders – Therapy Market Snapshot
Boston, MA ReportsWorldwide has announced the addition of a new report title Retinal Disorders – Therapy Market Snapshot to its growing collection of premium market research reports. A range of disorders, some of which share similar underlying pathologies, can affect the retina and lead to progressively worsening vision and eventual blindness. The retina is the layer of light-sensitive tissue at the back of the eye that converts light into impulses to the